Cracking the code of healthy aging: new approaches to staying healthy as we age

The Impact of Climate Change

Climate Change: Severe Droughts Require Action to Avoid a Food Crisis

Heart and Kidneys

Five Reasons to Care About the Risks of Chronic Kidney Disease

Innovation in Cell and Gene Therapy

Charting a New Course for Parkinson’s Disease

Merchants of Doubt

How Scientific Consensus is Being Systematically Undermined

Latest News

September 16, 2021

Not intended for U.S. and UK Media – ESMO Congress 2021:

Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer

August 31, 2021

Not intended for U.S. and UK Media

Bayer starts Phase III clinical development program OASIS with Elinzanetant

August 28, 2021

Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021

New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression

Our Stories

The following materials are not directed at or to be accessed by persons located in the United States, Australia, Canada or Japan. These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the

Bayer continues to provide on-site support

Bayer continues to provide on-site support

No limitations: Juergen Schrapps Journey to the Tokyo Paralympics

Worlds We Carry: The Microbiome Universe Right Under Your Nose

Lung cancer diagnosis and treatment

How screening, artificial intelligence and genomic testing can help to fight lung cancer

When normal is not normal – let’s talk about Women’s Health

Support and solidarity after devastating floods

#TeamBayer joins forces: “We can make it together”

Heart and Kidneys

Five Reasons to Care About the Risks of Chronic Kidney Disease